Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?

被引：4
|
作者：
D'Angelo, Salvatore [1 ]
Secondulfo, Mario [1 ]
De Cristofano, Raffaele [1 ]
Sorrentino, Paolo [1 ]
机构：
[1] SG Moscati Hosp, Liver Unit, I-83100 Avellino, Italy
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 14期
关键词：
Entecavir; Hepatocellular carcinoma; Hepatitis B virus; Liver function; Sorafenib; HEPATITIS-B-VIRUS; CIRRHOSIS; EFFICACY; INFECTION; THERAPY; CANCER;
D O I：
10.3748/wjg.v19.i14.2141
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码：2141 / 2143
页数：3
相关论文
共 50 条
  • [31] Combining telomerase inhibitors with sorafenib as a treatment strategy in advanced hepatocellular carcinoma
    Uldry, E.
    Faes, S.
    Santoro, T.
    Planche, A.
    Demartines, N.
    Dormond, O.
    BRITISH JOURNAL OF SURGERY, 2016, 103 : 22 - 22
  • [32] Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
    Choi, Joon-Il
    Imagawa, David K.
    Bhosale, Priya
    Bhargava, Puneet
    Tirkes, Temel
    Seery, Tara E.
    Lall, Chandana
    CLINICAL AND MOLECULAR HEPATOLOGY, 2014, 20 (02) : 218 - 222
  • [33] Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.
    Herman, Michael
    Zhang, Yuhua
    Wang, Lisa
    Sim, Hao-Wen
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma
    Hideaki Takeyama
    Toru Beppu
    Takaaki Higashi
    Takayoshi Kaida
    Kota Arima
    Katsunobu Taki
    Katsunori Imai
    Hidetoshi Nitta
    Hiromitsu Hayashi
    Shigeki Nakagawa
    Hirohisa Okabe
    Daisuke Hashimoto
    Akira Chikamoto
    Takatoshi Ishiko
    Motohiko Tanaka
    Yutaka Sasaki
    Hideo Baba
    Surgery Today, 2018, 48 : 431 - 438
  • [35] SAFETY AND EFFICACY OF SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Sacco, P. C.
    De Sanctis, R.
    Quadrini, S.
    Gori, B.
    Del, Signore E.
    Stumbo, L.
    Tedeschi, M.
    Falbo, P. T.
    Fulvi, A.
    Grassi, P.
    Sollami, R.
    Basile, M. L.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
    Miyahara, Koji
    Nouso, Kazuhiro
    Yamamoto, Kazuhide
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4151 - 4159
  • [37] Sorafenib for advanced-stage hepatocellular carcinoma
    Tomuleasa, Ciprian
    Cristea, Victor
    Irimie, Alexandru
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (03) : 346 - 347
  • [38] Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
    Koji Miyahara
    Kazuhiro Nouso
    Kazuhide Yamamoto
    World Journal of Gastroenterology, 2014, (15) : 4151 - 4159
  • [39] Treatment Strategy Based on Sorafenib for Advanced Hepatocellular Carcinoma Premising Subsequent Treatment with Regorafenib
    Tokunaga, Takayuki
    Tanaka, Motohiko
    Tanaka, Kentaro, II
    Narahara, Satoshi
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Kawasaki, Takeshi
    Setoyama, Hiroko
    Watanabe, Takehisa
    Tateyama, Masakuni
    Sasaki, Yutaka
    HEPATOLOGY, 2018, 68 : 839A - 840A
  • [40] Effectiveness of sorafenib in the treatment of hepatocellular carcinoma
    Salamanca, P.
    Magalhaes, H.
    Carneiro, F.
    Marques, D.
    Faustino, C.
    Sousa, N.
    Machado, M.
    Ferreira, P.
    Raimundo, A.
    Fragoso, M.
    Lara Santos, L.
    Pereira, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 52 - 52
12345